Molecular therapies for HCC: Looking outside the box

Area of Science:

• Hepatocellular Carcinoma (HCC) Treatment
• Oncology Drug Development
• Translational Cancer Research

Background:

• Sorafenib was the sole systemic therapy for unresectable HCC for years.
• Recent advances include lenvatinib, regorafenib, cabozantinib, ramucirumab, and immune checkpoint inhibitors.
• Lack of predictive biomarkers limits personalized treatment selection.

Purpose of the Study:

• To review novel combination strategies and molecular targets in advanced HCC.
• To discuss the potential interplay between antiangiogenic drugs and immunotherapy.
• To explore the future role of molecular therapies and biomarkers in HCC treatment.

Main Methods:

• Review of recent clinical trial data (Phase I, II, and III).
• Analysis of translational research integrating biological profiling and biomarker discovery.
• Focus on combination therapies including antiangiogenics and immune checkpoint inhibitors.

Main Results:

• Lenvatinib shows non-inferiority to sorafenib; other agents superior to placebo in refractory HCC.
• Early trials of bevacizumab/atezolizumab and lenvatinib/pembrolizumab combinations show promise.
• Novel molecular targets (TGF-β, MET, FGFR4) are under investigation with integrated biomarker strategies.

Conclusions:

• Combination therapies, particularly antiangiogenics with immunotherapy, are a key focus in advanced HCC.
• Identifying predictive biomarkers is crucial for selecting patients for specific molecular therapies.
• Emerging molecular therapies and combination strategies offer future hope for advanced HCC patients.